文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气消化、代谢与肾脏急症

重症监护室住院期间血糖轨迹与脓毒症相关急性呼吸窘迫综合征患者死亡率的关系

[Relationship between blood glucose trajectory during intensive care unit stay and mortality in patients with sepsis-associated acute respiratory distress syndrome].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2025-01-01
一句话结论在脓毒症相关ARDS患者中,ICU住院7天内持续高血糖(10.6-13.1 mmol/L)轨迹与28天、1年死亡率显著升高相关,低正常血糖轨迹死亡率最低。

该研究基于MIMIC-IV数据库,纳入3869例脓毒症相关ARDS患者,采用基于组的轨迹模型分析ICU入院7天内血糖轨迹,分为持续高血糖组(10.6-13.1 mmol/L,n=894)、中等血糖组(7.8-8.9 mmol/L,n=1452)和低正常血糖组(6.1-7.0 mmol/L,n=1523)。结果显示,低正常血糖组、中等血糖组、持续高血糖组的28天死亡率分别为11.42%、19.83%、25.50%(P<0.001),1年死亡率分别为23.31%、33.75%、39.49%(P<0.001)。以中等血糖组为参照,低正常血糖组院内死亡风险降低43.1%(OR=0.569,95%CI 0.445-0.726),ICU死亡风险降低42.0%(OR=0.580,95%CI 0.439-0.762)。三组7天内低血糖发生率无显著差异(P=0.893)。

要点

  • 脓毒症相关ARDS患者ICU住院7天内持续高血糖轨迹(10.6-13.1 mmol/L)与28天死亡率25.50%、1年死亡率39.49%显著相关。
  • 低正常血糖轨迹(6.1-7.0 mmol/L)患者28天死亡率11.42%、1年死亡率23.31%,为三组中最低。
  • 以中等血糖组(7.8-8.9 mmol/L)为参照,低正常血糖组院内死亡风险降低43.1%(OR=0.569,95%CI 0.445-0.726),ICU死亡风险降低42.0%(OR=0.580,95%CI 0.439-0.762)。
  • 三组7天内低血糖发生率分别为低正常血糖组2.82%、中等血糖组2.69%、持续高血糖组3.02%,无统计学显著差异(P=0.893)。
  • 中等血糖组与持续高血糖组相比,院内死亡和ICU死亡风险有降低趋势但未达统计学显著。

适用人群与场景

  • 基于MIMIC-IV数据库筛选的脓毒症相关ARDS患者,且ICU入院7天内具有每日血糖监测数据。
  • 共纳入3869例,中位年龄63.52(52.13,73.54)岁,男性占59.6%(2304/3869)。

诊断标准与关键阈值

  • 采用基于组的轨迹模型(GBTM)分析ICU入院7天内血糖轨迹,根据最小AIC、BIC、平均后验概率(AvePP)、正确分类几率(OCC)和组内成员比例(Prop)确定最佳分组数。
  • 最终分为三组:持续高血糖组(血糖维持于10.6-13.1 mmol/L,n=894)、中等血糖组(7.8-8.9 mmol/L,n=1452)、低正常血糖组(6.1-7.0 mmol/L,n=1523)。

研究设计与关键结果

  • 研究类型:基于MIMIC-IV数据库的回顾性队列研究(原文未明确单中心或多中心),样本量3869例脓毒症相关ARDS患者。
  • 28天死亡率:低正常血糖组11.42%(174/1523) vs 中等血糖组19.83%(288/1452) vs 持续高血糖组25.50%(228/894),χ²=82.545,P<0.001。
  • 1年死亡率:低正常血糖组23.31%(355/1523) vs 中等血糖组33.75%(490/1452) vs 持续高血糖组39.49%(353/894),χ²=77.376,P<0.001。
  • Kaplan-Meier分析显示,血糖轨迹越高,28天和1年累积生存率显著越低(Log-rank检验:χ²分别为83.221和85.022,均P<0.001)。
  • 院内死亡率:低正常血糖组9.65%(147/1523) vs 中等血糖组19.70%(286/1452) vs 持续高血糖组24.50%(219/894),χ²=102.020,P<0.001;ICU死亡率:低正常血糖组7.22%(110/1523) vs 中等血糖组16.05%(233/1452) vs 持续高血糖组20.13%(180/894),χ²=93.050,P<0.001。
  • 多因素Logistic回归(以持续高血糖组为参照)证实,低正常血糖组院内死亡和ICU死亡风险显著降低;中等血糖组死亡风险有降低趋势但差异未达统计学显著。
  • 以中等血糖组为参照,低正常血糖组院内死亡风险降低43.1%(OR=0.569,95%CI 0.445-0.726,P<0.001),ICU死亡风险降低42.0%(OR=0.580,95%CI 0.439-0.762,P<0.001)。
  • 7天内低血糖发生率:低正常血糖组2.82%(43/1523) vs 中等血糖组2.69%(39/1452) vs 持续高血糖组3.02%(27/894),χ²=0.226,P=0.893,无统计学显著差异。

证据类型、等级与局限

  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在脓毒症相关ARDS患者中,ICU住院7天内持续高血糖轨迹(10.6-13.1 mmol/L)与28天死亡率25.50%、1年死亡率39.49%显著相关,提示对此类血糖轨迹患者需加强关注。
  • 低正常血糖轨迹(6.1-7.0 mmol/L)患者28天死亡率11.42%、1年死亡率23.31%,为三组中最低,且与中等血糖组相比院内死亡风险降低43.1%(OR=0.569,95%CI 0.445-0.726)。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To explore the association between blood glucose trajectories within 7 days of intensive care unit (ICU) admission and mortality in patients with sepsis-associated acute respiratory distress syndrome (ARDS).

METHODS: Based on the MIMIC-IV database, sepsis-associated ARDS patients with daily blood glucose monitoring data within 7 days of ICU admission were selected. Blood glucose trajectories were analyzed using group-based trajectory modeling (GBTM), and the optimal number of groups was determined based on the minimum Akaike information criterion (AIC), Bayesian information criterion (BIC), average posterior probability (AvePP), odds of correct classification (OCC), and proportion of group membership (Prop). Baseline characteristics including demographics, comorbidities, severity scores, vital signs, laboratory indicators within the first 24 hours of ICU admission, and treatments were collected. Kaplan-Meier survival curves were used to compare 28-day and 1-year survival across trajectory groups. Multivariate Logistic regression was performed to evaluate the associations between glucose trajectory groups and in-hospital mortality, ICU mortality. The incidence of hypoglycemia within 7 days in the ICU was analyzed among different groups.

RESULTS: A total of 3 869 patients with sepsis-associated ARDS were included, with a median age of 63.52 (52.13, 73.54) years; 59.6% (2 304/3 869) were male. Based on glucose levels within 7 days, patients were categorized into three groups: persistent hyperglycemia group (glucose maintained at 10.6-13.1 mmol/L, n = 894), moderate glucose group (7.8-8.9 mmol/L, n = 1 452), and low-normal glucose group (6.1-7.0 mmol/L, n = 1 523). There were statistically significant differences in 28-day mortality and 1-year mortality among low-normal glucose group, moderate glucose group, and persistent hyperglycemia group [28-day mortality: 11.42% (174/1 523), 19.83% (288/1 452), 25.50% (228/894), χ 2 = 82.545, P < 0.001; 1-year mortality: 23.31% (355/1 523), 33.75% (490/1 452), 39.49% (353/894), χ 2 = 77.376, P < 0.001]. Kaplan-Meier analysis showed that higher glucose trajectories were associated with significantly lower 28-day and 1-year cumulative survival rates (Log-rank test: χ 2 were 83.221 and 85.022, both P < 0.001). There were statistically significant differences in in-hospital mortality and ICU mortality among the low-normal glucose group, moderate glucose group, and persistent hyperglycemia group [in-hospital mortality: 9.65% (147/1 523), 19.70% (286/1 452), 24.50% (219/894), χ 2 = 102.020, P < 0.001; ICU mortality: 7.22% (110/1 523), 16.05% (233/1 452), 20.13% (180/894), χ 2 = 93.050, P < 0.001]. Logistic regression confirmed that, using the persistent hyperglycemia group as the reference, the low-normal glucose group had significantly lower risks of in-hospital mortality and ICU mortality after multiple factor adjustment. Although the moderate glucose group showed a trend toward lower mortality, the differences were not statistically significant. Using the moderate glucose group as a reference, the low-normal glucose group had 43.1% lower in-hospital mortality [odds ratio (OR) = 0.569, 95% confidence interval (95%CI) was 0.445-0.726, P < 0.001] and 42.0% lower ICU mortality (OR = 0.580, 95%CI was 0.439-0.762, P < 0.001). There was no statistically significant difference in the incidence of hypoglycemia within 7 days of ICU admission among low-normal glucose group, moderate glucose group, and persistent hyperglycemia group [2.82% (43/1 523), 2.69% (39/1 452), 3.02% (27/894), χ 2 = 0.226, P = 0.893].

CONCLUSIONS: Blood glucose trajectories during ICU stay are closely associated with prognosis in patients with sepsis-associated ARDS. Persistent hyperglycemia (10.6-13.1 mmol/L) is linked to significantly higher short- and long-term mortality.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Yang Y, Wang H, Liu J, et al. [Relationship between blood glucose trajectory during intensive care unit stay and mortality in patients with sepsis-associated acute respiratory distress syndrome]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 41331887. doi:10.3760/cma.j.cn121430-20250720-00121

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。